EGFR and neoplasm: SAH-JGZ4 reduced the tumor-initiating cell (TIC) frequency by sixfold (1/TIC from ~93 cells to ~546 cells) (Fig. 7j, k), suggesting that targeting EGFR stability is a potential strategy to inhibit the stemness of lung cancer cells.